Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
Recruiting · NCT04798651 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Bordeaux
View the official record on ClinicalTrials.gov →Interventions studied
blood samplecerebro-spinal fluid
What this trial is about
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- male or female subjects ;
- Age ≥ 18 years;
- subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome;
- patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose;
- affiliated to an health insurance system;
- and who agree to participate in the study.
Exclusion criteria
- Pregnant or breastfeeding women,
- patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Where it is running
1 location listed.
- CHU de Bordeaux - service de neurologie - Bordeaux, France